{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:05:42Z","timestamp":1783191942460,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MEDICE Arzneimittel P\u00fctter GmbH & Co KG"},{"name":"Biocodex SAS, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics &amp; Antimicro. Prot."],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Irritable bowel syndrome (IBS) is one of the disorders most frequently diagnosed by gastroenterologists. Probiotics are promising tools for the management of IBS. The objective of the present study was to evaluate the effectiveness and tolerability of a probiotic (<jats:italic>Bifidobacterium longum<\/jats:italic> 35624<jats:sup>\u00ae<\/jats:sup>) in adults (aged 18 or over) with IBS (as defined by the Rome IV criteria). In an open-label, observational, post-market study conducted in Germany, adults with IBS and a prior recommendation for the intake of <jats:italic>B. longum<\/jats:italic> 35624<jats:sup>\u00ae<\/jats:sup> were recruited by family physicians. During the 8-week course of treatment, the study participants filled out a weekly questionnaire that enabled calculation of a total IBS symptom score (TISS, the sum of abdominal pain, bloating, passage of gas, constipation, and diarrhea individual symptom scores) and the well-known IBS severity scoring system (IBS-SSS) score. Thirty-seven patients were included. The course of <jats:italic>B. longum<\/jats:italic> 35624<jats:sup>\u00ae<\/jats:sup> was associated with a significant reduction (43.4%) in the TISS vs. baseline. The mean individual symptom grades for passage of gas and bloating fell significantly from \u201cmoderate\u201d at baseline to \u201cvery mild to mild\u201d after 8 weeks of treatment, whereas those for abdominal pain and diarrhea fell significantly from \u201cmild to moderate\u201d to \u201cvery mild to mild.\u201d Over 60% of the participants achieved clinically meaningful reductions in the TISS (&gt;\u200930%) and the IBS-SSS score (&gt;\u200950 points). The effectiveness of <jats:italic>B. longum<\/jats:italic> 35624<jats:sup>\u00ae<\/jats:sup> was rated as \u201cgood to satisfactory\u201d by study participants and the investigating physicians. One mild adverse event (nausea) was potentially linked to the study treatment. We conclude that an 8-week course of <jats:italic>B. longum<\/jats:italic> 35624<jats:sup>\u00ae<\/jats:sup> was associated with significant, clinically meaningful symptom relief in a typical population of adult patients with IBS.<\/jats:p>","DOI":"10.1007\/s12602-023-10151-w","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T06:02:32Z","timestamp":1694584952000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An 8-Week Course of Bifidobacterium longum 35624\u00ae Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome"],"prefix":"10.1007","volume":"17","author":[{"given":"Marion","family":"Lenoir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wienke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0769-0451","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Fardao-Beyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Roese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"10151_CR1","doi-asserted-by":"crossref","first-page":"12144","DOI":"10.3748\/wjg.v20.i34.12144","volume":"20","author":"RL Soares","year":"2014","unstructured":"Soares RL (2014) Irritable bowel syndrome: a clinical review. World J Gastroenterol 20:12144\u201312160","journal-title":"World J Gastroenterol"},{"issue":"99\u2013114","key":"10151_CR2","volume":"160","author":"AD Sperber","year":"2021","unstructured":"Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al (2021) Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 160(99\u2013114):e3","journal-title":"Gastroenterology"},{"key":"10151_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jcm6110099","volume":"6","author":"BE Lacy","year":"2017","unstructured":"Lacy BE, Patel NK (2017) Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 6:99","journal-title":"J Clin Med"},{"key":"10151_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","volume":"17","author":"CJ Black","year":"2020","unstructured":"Black CJ, Ford AC (2020) Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 17:473\u2013486","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10151_CR5","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","volume":"2","author":"P Enck","year":"2016","unstructured":"Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA et al (2016) Irritable bowel syndrome. Nat Rev Dis Primers 2:16014","journal-title":"Nat Rev Dis Primers"},{"key":"10151_CR6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.25122\/jml-2022-0028","volume":"15","author":"AN Galica","year":"2022","unstructured":"Galica AN, Galica R, Dumitrascu DL (2022) Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life 15:174\u2013179","journal-title":"J Med Life"},{"key":"10151_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12967-022-03365-z","volume":"20","author":"P Ghaffari","year":"2022","unstructured":"Ghaffari P, Shoaie S, Nielsen LK (2022) Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. J Transl Med 20:173","journal-title":"J Transl Med"},{"key":"10151_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1590\/s0004-2803.202100000-20","volume":"58","author":"ACL Scaciota","year":"2021","unstructured":"Scaciota ACL, Matos D, Rosa MMB, Colovati MES, Bellotto E, Martimbianco ALC (2021) Interventions for the treatment of irritable bowel syndrome: a review of Cochrane systematic reviews. Arq Gastroenterol 58:120\u2013126","journal-title":"Arq Gastroenterol"},{"key":"10151_CR9","volume":"13","author":"CR Xie","year":"2022","unstructured":"Xie CR, Tang B, Shi YZ, Peng WY, Ye K, Tao QF et al (2022) Low FODMAP diet and probiotics in irritable bowel syndrome: a systematic review with network meta-analysis. Front Pharmacol 13:853011","journal-title":"Front Pharmacol"},{"key":"10151_CR10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S2468-1253(21)00023-6","volume":"6","author":"M Bosman","year":"2021","unstructured":"Bosman M, Elsenbruch S, Corsetti M, Tack J, Simren M, Winkens B et al (2021) The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:459\u2013473","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10151_CR11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12325-018-0673-5","volume":"35","author":"BK Rodino-Janeiro","year":"2018","unstructured":"Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garcia R, Santos J (2018) A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther 35:289\u2013310","journal-title":"Adv Ther"},{"key":"10151_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pain.2009.06.017","volume":"146","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Zhang B, Verne GN (2009) Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 146:41\u201346","journal-title":"Pain"},{"key":"10151_CR13","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00243.2009","volume":"298","author":"CL Ohland","year":"2010","unstructured":"Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298:G807\u2013G819","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10151_CR14","first-page":"e24240","volume":"14","author":"L Satish Kumar","year":"2022","unstructured":"Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S, Barkhane Z, Elmadi J (2022) Probiotics in irritable bowel syndrome: a review of their therapeutic role. Cureus 14:e24240","journal-title":"Cureus"},{"key":"10151_CR15","doi-asserted-by":"crossref","first-page":"1053958","DOI":"10.3389\/fmicb.2022.1053958","volume":"13","author":"C Wiegers","year":"2022","unstructured":"Wiegers C, Veerman MA, Brummer RJ, Larsen OFA (2022) Reviewing the state of the art of probiotics as clinical modalities for brain-gut-microbiota axis associated disorders. Front Microbiol 13:1053958","journal-title":"Front Microbiol"},{"key":"10151_CR16","volume":"12","author":"T Zhang","year":"2022","unstructured":"Zhang T, Zhang C, Zhang J, Sun F, Duan L (2022) Efficacy of probiotics for irritable bowel syndrome: a systematic review and network meta-analysis. Front Cell Infect Microbiol 12:859967","journal-title":"Front Cell Infect Microbiol"},{"key":"10151_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dld.2022.11.015","volume":"55","author":"G Barbara","year":"2022","unstructured":"Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F et al (2022) Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis 55:187\u2013207","journal-title":"Dig Liver Dis"},{"key":"10151_CR18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00535-020-01746-z","volume":"56","author":"S Fukudo","year":"2021","unstructured":"Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T et al (2021) Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56:193\u2013217","journal-title":"J Gastroenterol"},{"key":"10151_CR19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/jgh.14268","volume":"33","author":"KA Gwee","year":"2018","unstructured":"Gwee KA, Lee WW, Ling KL, Ooi CJ, Quak SH, Dan YY et al (2018) Consensus and contentious statements on the use of probiotics in clinical practice: a south east Asian gastro-neuro motility association working team report. J Gastroenterol Hepatol 33:1707\u20131716","journal-title":"J Gastroenterol Hepatol"},{"key":"10151_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD et al (2021) ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 116:17\u201344","journal-title":"Am J Gastroenterol"},{"key":"10151_CR21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jcag\/gwy071","volume":"2","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L et al (2019) Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2:6\u201329","journal-title":"J Can Assoc Gastroenterol"},{"key":"10151_CR22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MCG.0000000000000653","volume":"50","author":"EM Quigley","year":"2016","unstructured":"Quigley EM, Fried M, Gwee KA, Khalif I, Hungin AP, Lindberg G et al (2016) World Gastroenterology Organisation global guidelines irritable bowel syndrome: a global perspective update September 2015. J Clin Gastroenterol 50:704\u2013713","journal-title":"J Clin Gastroenterol"},{"key":"10151_CR23","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","volume":"70","author":"DH Vasant","year":"2021","unstructured":"Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M et al (2021) British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70:1214\u20131240","journal-title":"Gut"},{"key":"10151_CR24","first-page":"A25","volume":"66","author":"S Healy","year":"2017","unstructured":"Healy S, Casey M, Kiely B, Quigley EM, Shanahan F, Murphy EF (2017) 68 The bifidobacterium longum 35624 culture transits in high numbers through the human gut. Gut 66:A25","journal-title":"Gut"},{"key":"10151_CR25","doi-asserted-by":"crossref","first-page":"e0162983","DOI":"10.1371\/journal.pone.0162983","volume":"11","author":"F Altmann","year":"2016","unstructured":"Altmann F, Kosma P, O\u2019Callaghan A, Leahy S, Bottacini F, Molloy E et al (2016) Genome analysis and characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624. PLoS One 11:e0162983","journal-title":"PLoS One"},{"key":"10151_CR26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","volume":"101","author":"PJ Whorwell","year":"2006","unstructured":"Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O\u2019Mahony L et al (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:1581\u20131590","journal-title":"Am J Gastroenterol"},{"key":"10151_CR27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","volume":"128","author":"L O'Mahony","year":"2005","unstructured":"O\u2019Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541\u2013551","journal-title":"Gastroenterology"},{"key":"10151_CR28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3748\/wjg.v28.i7.732","volume":"28","author":"JM Sabat\u00e9","year":"2022","unstructured":"Sabat\u00e9 JM, Iglicki F (2022) Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 28:732\u2013744","journal-title":"World J Gastroenterol"},{"key":"10151_CR29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCG.0b013e3182549092","volume":"46","author":"F Guarner","year":"2012","unstructured":"Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A et al (2012) World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 46:468\u2013481","journal-title":"J Clin Gastroenterol"},{"key":"10151_CR30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/gmic.24196","volume":"4","author":"D Charbonneau","year":"2013","unstructured":"Charbonneau D, Gibb RD, Quigley EM (2013) Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 4:201\u2013211","journal-title":"Gut Microbes"},{"key":"10151_CR31","first-page":"8030297","volume":"2021","author":"S Yao","year":"2021","unstructured":"Yao S, Zhao Z, Wang W, Liu X (2021) Bifidobacterium Longum: protection against inflammatory bowel disease. J Immunol Res 2021:8030297","journal-title":"J Immunol Res"},{"key":"10151_CR32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pathogens11090986","volume":"11","author":"A Rueda-Robles","year":"2022","unstructured":"Rueda-Robles A, Rodriguez-Lara A, Meyers MS, Saez-Lara MJ, Alvarez-Mercado AI (2022) Effect of probiotics on host-microbiota in bacterial infections. Pathogens 11:986","journal-title":"Pathogens"},{"key":"10151_CR33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/gutjnl-2011-300936","volume":"61","author":"P Konieczna","year":"2012","unstructured":"Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F et al (2012) Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 61:354\u2013366","journal-title":"Gut"},{"key":"10151_CR34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4161\/gmic.25487","volume":"4","author":"D Groeger","year":"2013","unstructured":"Groeger D, O\u2019Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B et al (2013) Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4:325\u2013339","journal-title":"Gut Microbes"},{"key":"10151_CR35","first-page":"338","volume":"27","author":"LE Miller","year":"2014","unstructured":"Miller LE (2014) Study design considerations for irritable bowel syndrome clinical trials. Ann Gastroenterol 27:338\u2013345","journal-title":"Ann Gastroenterol"},{"key":"10151_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett P, Kjaer J, Broich K, Cooke E (2022) Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther 111:21\u201323","journal-title":"Clin Pharmacol Ther"},{"key":"10151_CR37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11:395\u2013402","journal-title":"Aliment Pharmacol Ther"},{"key":"10151_CR38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2982.2005.00650.x","volume":"17","author":"SM Patel","year":"2005","unstructured":"Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L et al (2005) The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 17:332\u2013340","journal-title":"Neurogastroenterol Motil"},{"key":"10151_CR39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","volume":"32","author":"AC Ford","year":"2010","unstructured":"Ford AC, Moayyedi P (2010) Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 32:144\u2013158","journal-title":"Aliment Pharmacol Ther"},{"key":"10151_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3920\/BM2021.0123","volume":"13","author":"AM van der Geest","year":"2022","unstructured":"van der Geest AM, Schukking I, Brummer RJM, van de Burgwal LHM, Larsen OFA (2022) Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Benef Microbes 13:183\u2013194","journal-title":"Benef Microbes"},{"key":"10151_CR41","first-page":"1191","volume":"36","author":"LQ Bian","year":"2016","unstructured":"Bian LQ, Lu F, Li ZH, Ll BS, Gao R, Wang FY et al (2016) Analysis of response of IBS-SSS, AR, and IBS-QOL in IBS clinical effect evaluation. Zhongguo Zhong Xi Yi Jie He Za Zhi 36:1191\u20131196","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"10151_CR42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ajg.2009.13","volume":"104","author":"MC Passos","year":"2009","unstructured":"Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT et al (2009) Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol 104:912\u2013919","journal-title":"Am J Gastroenterol"},{"key":"10151_CR43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1055\/s-0033-1335260","volume":"51","author":"C Betz","year":"2013","unstructured":"Betz C, Mannsdorfer K, Bischoff SC (2013) Validation of the IBS-SSS. Z Gastroenterol 51:1171\u20131176","journal-title":"Z Gastroenterol"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-023-10151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12602-023-10151-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-023-10151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:27:11Z","timestamp":1739831231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12602-023-10151-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10151"],"URL":"https:\/\/doi.org\/10.1007\/s12602-023-10151-w","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"22 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of the study, Marion Lenoir was a salaried employee of Biocodex SAS. As a study physician, J\u00f6rg Wienke received fees from MEDICE Arzneimittel P\u00fctter GmbH & Co KG for his medical services during the study. Fr\u00e9d\u00e9rique Fardao-Beyler is salaried employee of Biocodex SAS. Nadine Roese is a salaried employee of MEDICE Arzneimittel P\u00fctter GmbH & Co KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}